NeOnc Technologies and the Department of Health – Abu Dhabi Sign MoU to Advance Brain Cancer Research and Proposed Clinical Collaboration
NeOnc Technologies signed a non-binding Memorandum of Understanding with the Department of Health – Abu Dhabi to cooperate on CNS oncology research, specialist training, real-world evidence, and assessment of clinical trial opportunities in the Emirate. The MoU builds on June 2026 DoH IND clearances for NEO100 and NEO212 and on NeOnc's Compassionate Care program, through which two children in Abu Dhabi are receiving investigational NEO100, with a third expected from India this week. The company is working to open a Phase 1 NEO100 study in Abu Dhabi.
Key figures
- Drug Name
- NEO100
- Phase Of Trial
- Phase 1-2 (NEO100-01/02/03 protocols)
- Mou term years
- 2
- Compassionate care patients uae
- 3
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.